Identifying	O
CNVs	B:C0009850
in	O
15q11q13	O
and	O
16p11.2	O
of	O
Patients	O
with	O
Seizures	O
Increases	O
the	O
Rates	O
of	O
Detecting	O
Pathogenic	O
Changes	O
Chromosomal	O
changes	O
are	O
frequently	O
observed	O
in	O
patients	O
with	O
syndromic	O
seizures	I:C0036572
.	O

Identifying	O
CNVs	O
in	O
15q11q13	B:C1953345
and	O
16p11.2	O
of	O
Patients	O
with	O
Seizures	O
Increases	O
the	O
Rates	O
of	O
Detecting	O
Pathogenic	O
Changes	O
Chromosomal	O
changes	O
are	O
frequently	O
observed	O
in	O
patients	O
with	O
syndromic	O
seizures	I:C0036572
.	O

Identifying	O
CNVs	O
in	O
15q11q13	O
and	O
16p11.2	B:C1520678
of	O
Patients	O
with	O
Seizures	O
Increases	O
the	O
Rates	O
of	O
Detecting	O
Pathogenic	O
Changes	O
Chromosomal	O
changes	O
are	O
frequently	O
observed	O
in	O
patients	O
with	O
syndromic	O
seizures	I:C0036572
.	O

Identifying	O
CNVs	O
in	O
15q11q13	O
and	O
16p11.2	O
of	O
Patients	O
with	O
Seizures	B:C0036572
Increases	O
the	O
Rates	O
of	O
Detecting	O
Pathogenic	O
Changes	O
Chromosomal	O
changes	O
are	O
frequently	O
observed	O
in	O
patients	O
with	O
syndromic	O
seizures	I:C0036572
.	O

Identifying	O
CNVs	O
in	O
15q11q13	O
and	O
16p11.2	O
of	O
Patients	O
with	O
Seizures	O
Increases	O
the	O
Rates	O
of	O
Detecting	B:C1511790
Pathogenic	O
Changes	O
Chromosomal	O
changes	O
are	O
frequently	O
observed	O
in	O
patients	O
with	O
syndromic	O
seizures	I:C0036572
.	O

Identifying	O
CNVs	O
in	O
15q11q13	O
and	O
16p11.2	O
of	O
Patients	O
with	O
Seizures	O
Increases	O
the	O
Rates	O
of	O
Detecting	O
Pathogenic	O
Changes	O
Chromosomal	O
changes	O
are	O
frequently	O
observed	O
in	O
patients	O
with	O
syndromic	B:C0036572
seizures	I:C0036572
.	O

Understanding	O
the	O
genetic	O
etiology	O
of	O
this	O
pathology	B:C0677042
is	O
crucial	O
for	O
the	O
guidance	O
and	O
genetic	O
counseling	I:C0017382
of	O
families	O
as	O
well	O
as	O
for	O
the	O
establishment	O
of	O
appropriate	O
treatment	I:C3640049
.	O

Understanding	O
the	O
genetic	O
etiology	O
of	O
this	O
pathology	O
is	O
crucial	O
for	O
the	O
guidance	B:C3854153
and	O
genetic	O
counseling	I:C0017382
of	O
families	O
as	O
well	O
as	O
for	O
the	O
establishment	O
of	O
appropriate	O
treatment	I:C3640049
.	O

Understanding	O
the	O
genetic	O
etiology	O
of	O
this	O
pathology	O
is	O
crucial	O
for	O
the	O
guidance	O
and	O
genetic	B:C0017382
counseling	I:C0017382
of	O
families	O
as	O
well	O
as	O
for	O
the	O
establishment	O
of	O
appropriate	O
treatment	I:C3640049
.	O

Understanding	O
the	O
genetic	O
etiology	O
of	O
this	O
pathology	O
is	O
crucial	O
for	O
the	O
guidance	O
and	O
genetic	O
counseling	I:C0017382
of	O
families	O
as	O
well	O
as	O
for	O
the	O
establishment	O
of	O
appropriate	B:C3640049
treatment	I:C3640049
.	O

A	O
combination	O
of	O
MLPA	B:C3494189
kits	I:C3494189
was	O
used	O
to	O
identify	O
pathogenic	O
CNVs	O
in	O
a	O
group	O
of	O
70	O
syndromic	O
patients	O
with	O
seizures	O
.	O

A	O
combination	O
of	O
MLPA	O
kits	I:C3494189
was	O
used	O
to	O
identify	O
pathogenic	O
CNVs	B:C0009850
in	O
a	O
group	O
of	O
70	O
syndromic	O
patients	O
with	O
seizures	O
.	O

A	O
combination	O
of	O
MLPA	O
kits	I:C3494189
was	O
used	O
to	O
identify	O
pathogenic	O
CNVs	O
in	O
a	O
group	O
of	O
70	O
syndromic	O
patients	O
with	O
seizures	B:C0036572
.	O

Initially	O
,	O
a	O
screening	B:C0220908
was	O
performed	O
for	O
subtelomeric	O
changes	O
(	O
MLPA	O
P036	I:C3494189
and	O
P070	O
kits	I:C3494189
)	O
and	O
for	O
the	O
regions	O
most	O
frequently	O
related	O
to	O
microdeletion	O
/	O
microduplication	O
syndromes	I:C0039082
(	O
MLPA	O
P064	I:C3494189
)	O
.	O

Initially	O
,	O
a	O
screening	O
was	O
performed	O
for	O
subtelomeric	B:C1953345
changes	O
(	O
MLPA	O
P036	I:C3494189
and	O
P070	O
kits	I:C3494189
)	O
and	O
for	O
the	O
regions	O
most	O
frequently	O
related	O
to	O
microdeletion	O
/	O
microduplication	O
syndromes	I:C0039082
(	O
MLPA	O
P064	I:C3494189
)	O
.	O

Initially	O
,	O
a	O
screening	O
was	O
performed	O
for	O
subtelomeric	O
changes	O
(	O
MLPA	B:C3494189
P036	I:C3494189
and	O
P070	O
kits	I:C3494189
)	O
and	O
for	O
the	O
regions	O
most	O
frequently	O
related	O
to	O
microdeletion	O
/	O
microduplication	O
syndromes	I:C0039082
(	O
MLPA	O
P064	I:C3494189
)	O
.	O

Initially	O
,	O
a	O
screening	O
was	O
performed	O
for	O
subtelomeric	O
changes	O
(	O
MLPA	O
P036	I:C3494189
and	O
P070	B:C3494189
kits	I:C3494189
)	O
and	O
for	O
the	O
regions	O
most	O
frequently	O
related	O
to	O
microdeletion	O
/	O
microduplication	O
syndromes	I:C0039082
(	O
MLPA	O
P064	I:C3494189
)	O
.	O

Initially	O
,	O
a	O
screening	O
was	O
performed	O
for	O
subtelomeric	O
changes	O
(	O
MLPA	O
P036	I:C3494189
and	O
P070	O
kits	I:C3494189
)	O
and	O
for	O
the	O
regions	B:C1953345
most	O
frequently	O
related	O
to	O
microdeletion	O
/	O
microduplication	O
syndromes	I:C0039082
(	O
MLPA	O
P064	I:C3494189
)	O
.	O

Initially	O
,	O
a	O
screening	O
was	O
performed	O
for	O
subtelomeric	O
changes	O
(	O
MLPA	O
P036	I:C3494189
and	O
P070	O
kits	I:C3494189
)	O
and	O
for	O
the	O
regions	O
most	O
frequently	O
related	O
to	O
microdeletion	O
/	O
microduplication	B:C0039082
syndromes	I:C0039082
(	O
MLPA	O
P064	I:C3494189
)	O
.	O

Initially	O
,	O
a	O
screening	O
was	O
performed	O
for	O
subtelomeric	O
changes	O
(	O
MLPA	O
P036	I:C3494189
and	O
P070	O
kits	I:C3494189
)	O
and	O
for	O
the	O
regions	O
most	O
frequently	O
related	O
to	O
microdeletion	O
/	O
microduplication	O
syndromes	I:C0039082
(	O
MLPA	B:C3494189
P064	I:C3494189
)	O
.	O

Subsequently	O
,	O
the	O
MLPA	B:C3494189
P343	I:C3494189
was	O
used	O
to	O
identify	O
alterations	O
in	O
the	O
15q11q13	O
,	O
16p11.2	O
,	O
and	O
22q13	O
regions	I:C1521113
.	O

Subsequently	O
,	O
the	O
MLPA	O
P343	I:C3494189
was	O
used	O
to	O
identify	O
alterations	O
in	O
the	O
15q11q13	B:C1953345
,	O
16p11.2	O
,	O
and	O
22q13	O
regions	I:C1521113
.	O

Subsequently	O
,	O
the	O
MLPA	O
P343	I:C3494189
was	O
used	O
to	O
identify	O
alterations	O
in	O
the	O
15q11q13	O
,	O
16p11.2	B:C1520678
,	O
and	O
22q13	O
regions	I:C1521113
.	O

Subsequently	O
,	O
the	O
MLPA	O
P343	I:C3494189
was	O
used	O
to	O
identify	O
alterations	O
in	O
the	O
15q11q13	O
,	O
16p11.2	O
,	O
and	O
22q13	B:C1521113
regions	I:C1521113
.	O

Screening	B:C0220908
with	O
MLPA	O
P343	I:C3494189
allowed	O
a	O
10	O
-	O
15.7	O
%	O
increase	O
in	O
the	O
detection	O
rate	O
of	O
CNVs	O
reinforcing	O
the	O
importance	O
of	O
investigating	O
changes	O
in	O
15q11q13	O
and	O
16p11.2	O
in	O
syndromic	O
patients	O
with	O
seizures	O
.	O

Screening	O
with	O
MLPA	B:C3494189
P343	I:C3494189
allowed	O
a	O
10	O
-	O
15.7	O
%	O
increase	O
in	O
the	O
detection	O
rate	O
of	O
CNVs	O
reinforcing	O
the	O
importance	O
of	O
investigating	O
changes	O
in	O
15q11q13	O
and	O
16p11.2	O
in	O
syndromic	O
patients	O
with	O
seizures	O
.	O

Screening	O
with	O
MLPA	O
P343	I:C3494189
allowed	O
a	O
10	O
-	O
15.7	O
%	O
increase	O
in	O
the	O
detection	B:C1511790
rate	O
of	O
CNVs	O
reinforcing	O
the	O
importance	O
of	O
investigating	O
changes	O
in	O
15q11q13	O
and	O
16p11.2	O
in	O
syndromic	O
patients	O
with	O
seizures	O
.	O

Screening	O
with	O
MLPA	O
P343	I:C3494189
allowed	O
a	O
10	O
-	O
15.7	O
%	O
increase	O
in	O
the	O
detection	O
rate	O
of	O
CNVs	B:C0009850
reinforcing	O
the	O
importance	O
of	O
investigating	O
changes	O
in	O
15q11q13	O
and	O
16p11.2	O
in	O
syndromic	O
patients	O
with	O
seizures	O
.	O

Screening	O
with	O
MLPA	O
P343	I:C3494189
allowed	O
a	O
10	O
-	O
15.7	O
%	O
increase	O
in	O
the	O
detection	O
rate	O
of	O
CNVs	O
reinforcing	O
the	O
importance	O
of	O
investigating	O
changes	O
in	O
15q11q13	B:C1953345
and	O
16p11.2	O
in	O
syndromic	O
patients	O
with	O
seizures	O
.	O

Screening	O
with	O
MLPA	O
P343	I:C3494189
allowed	O
a	O
10	O
-	O
15.7	O
%	O
increase	O
in	O
the	O
detection	O
rate	O
of	O
CNVs	O
reinforcing	O
the	O
importance	O
of	O
investigating	O
changes	O
in	O
15q11q13	O
and	O
16p11.2	B:C1520678
in	O
syndromic	O
patients	O
with	O
seizures	O
.	O

Screening	O
with	O
MLPA	O
P343	I:C3494189
allowed	O
a	O
10	O
-	O
15.7	O
%	O
increase	O
in	O
the	O
detection	O
rate	O
of	O
CNVs	O
reinforcing	O
the	O
importance	O
of	O
investigating	O
changes	O
in	O
15q11q13	O
and	O
16p11.2	O
in	O
syndromic	O
patients	O
with	O
seizures	B:C0036572
.	O

We	O
also	O
demonstrated	O
that	O
the	O
MLPA	B:C3494189
technique	I:C3494189
is	O
an	O
alternative	O
with	O
a	O
great	O
diagnostic	O
potential	O
,	O
and	O
we	O
proposed	O
its	O
use	O
as	O
part	O
of	O
the	O
initial	O
assessment	O
of	O
syndromic	O
patients	O
with	O
seizures	O
.	O

We	O
also	O
demonstrated	O
that	O
the	O
MLPA	O
technique	I:C3494189
is	O
an	O
alternative	O
with	O
a	O
great	O
diagnostic	O
potential	O
,	O
and	O
we	O
proposed	O
its	O
use	O
as	O
part	O
of	O
the	O
initial	O
assessment	O
of	O
syndromic	O
patients	O
with	O
seizures	B:C0036572
.	O

